Cooper E, Whalen C, Beeby N, Negron-Del Valle J, Phillips D, Snyder-Mackler N
Anim Behav. 2025; 219.
PMID: 39829684
PMC: 11741183.
DOI: 10.1016/j.anbehav.2024.10.035.
Su L, Zhang J, Peng Z
Ren Fail. 2022; 44(1):1280-1288.
PMID: 35930243
PMC: 9359166.
DOI: 10.1080/0886022X.2022.2107544.
Ozdirik B, Maibier M, Scherf M, Nicklaus J, Frohme J, Puengel T
J Clin Med. 2022; 11(9).
PMID: 35566603
PMC: 9105770.
DOI: 10.3390/jcm11092479.
Schmidt T, Albanna W, Weiss M, Veldeman M, Conzen C, Nikoubashman O
Front Neurol. 2022; 13:841024.
PMID: 35359651
PMC: 8960720.
DOI: 10.3389/fneur.2022.841024.
Dowsett J, Didriksen M, von Stemann J, Larsen M, Thorner L, Sorensen E
Sci Rep. 2022; 12(1):1672.
PMID: 35102231
PMC: 8803845.
DOI: 10.1038/s41598-022-05658-1.
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
Hartmann Rasmussen L, Petersen J, Eugen-Olsen J
Front Immunol. 2021; 12:780641.
PMID: 34925360
PMC: 8674945.
DOI: 10.3389/fimmu.2021.780641.
Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.
Dowsett J, Ferkingstad E, Hartmann Rasmussen L, Thorner L, Magnusson M, Sugden K
Commun Biol. 2021; 4(1):655.
PMID: 34079037
PMC: 8172928.
DOI: 10.1038/s42003-021-02144-8.
Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.
Azam T, Shadid H, Blakely P, OHayer P, Berlin H, Pan M
J Am Soc Nephrol. 2020; 31(11):2725-2735.
PMID: 32963090
PMC: 7608953.
DOI: 10.1681/ASN.2020060829.
Urinary suPAR: a non-invasive biomarker of infection and tissue inflammation for use in studies of large free-ranging mammals.
Higham J, Stahl-Hennig C, Heistermann M
R Soc Open Sci. 2020; 7(2):191825.
PMID: 32257339
PMC: 7062102.
DOI: 10.1098/rsos.191825.
The Diagnostic and Prognostic Value of suPAR in Patients with Sepsis: A Systematic Review and Meta-Analysis.
Huang Q, Xiong H, Yan P, Shuai T, Liu J, Zhu L
Shock. 2019; 53(4):416-425.
PMID: 31490358
PMC: 7069396.
DOI: 10.1097/SHK.0000000000001434.
MeSsAGe risk score: tool for renal biopsy decision in steroid-dependent nephrotic syndrome.
Chan C, Resontoc L, Qader M, Chan Y, Liu I, Lau P
Pediatr Res. 2019; 85(4):477-483.
PMID: 30659270
DOI: 10.1038/s41390-019-0277-z.
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Mahmood N, Mihalcioiu C, Rabbani S
Front Oncol. 2018; 8:24.
PMID: 29484286
PMC: 5816037.
DOI: 10.3389/fonc.2018.00024.
Effects of Acute Exercise on Circulating Soluble Form of the Urokinase Receptor in Patients With Major Depressive Disorder.
Gustafsson A, Ventorp F, Wisen A, Ohlsson L, Ljunggren L, Westrin A
Biomark Insights. 2017; 12:1177271917704193.
PMID: 28469403
PMC: 5397280.
DOI: 10.1177/1177271917704193.
Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.
Ni W, Han Y, Zhao J, Cui J, Wang K, Wang R
Sci Rep. 2016; 6:39481.
PMID: 27991579
PMC: 5172370.
DOI: 10.1038/srep39481.
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.
Boonstra M, de Geus S, Prevoo H, Hawinkels L, van de Velde C, Kuppen P
Biomark Cancer. 2016; 8:119-133.
PMID: 27721658
PMC: 5040425.
DOI: 10.4137/BIC.S38542.
The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders.
Vasarhelyi B, Toldi G, Balog A
EJIFCC. 2016; 27(2):122-9.
PMID: 27683525
PMC: 4975228.
Soluble Urokinase Receptor and Chronic Kidney Disease.
Hayek S, Sever S, Ko Y, Trachtman H, Awad M, Wadhwani S
N Engl J Med. 2015; 373(20):1916-25.
PMID: 26539835
PMC: 4701036.
DOI: 10.1056/NEJMoa1506362.
Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department.
Casagranda I, Vendramin C, Callegari T, Vidali M, Calabresi A, Ferrandu G
Intern Emerg Med. 2015; 10(6):725-30.
PMID: 26156446
DOI: 10.1007/s11739-015-1268-7.
Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants.
Haastrup E, Grau K, Eugen-Olsen J, Thorball C, Kessing L, Ullum H
PLoS One. 2014; 9(10):e110555.
PMID: 25329298
PMC: 4203805.
DOI: 10.1371/journal.pone.0110555.
Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.
Outinen T, Makela S, Huttunen R, Maenpaa N, Libraty D, Vaheri A
J Intern Med. 2014; 276(4):387-95.
PMID: 24717117
PMC: 4172514.
DOI: 10.1111/joim.12257.